The PE Ratio as of September 2024 (TTM) for Kronos Bio, Inc. (KRON) is -0.57

According to Kronos Bio, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.57. This represents a change of -25.14% compared to the average of -0.76 of the last 4 quarters.

Kronos Bio, Inc. (KRON) Historical PE Ratio (quarterly & annually)

How has KRON PE Ratio performed in the past?

The mean historical PE Ratio of Kronos Bio, Inc. over the last ten years is -39.88. The current -0.57 PE Ratio has changed 42.94% with respect to the historical average. Over the past ten years (40 quarters), KRON's PE Ratio was at its highest in in the September 2023 quarter at -0.60. The PE Ratio was at its lowest in in the September 2019 quarter at -47.98.

Kronos Bio, Inc. (KRON) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Kronos Bio, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kronos Bio, Inc. (KRON) Average PE Ratio

How has KRON PE Ratio performed in the past?

The current PE Ratio of Kronos Bio, Inc. (KRON) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Kronos Bio, Inc. (KRON) PE Ratio vs. Peers

How is KRON’s PE Ratio compared to its peers?

Kronos Bio, Inc.’s PE Ratio is less than Cyclerion Therapeutics, Inc. (2.44), greater than Larimar Therapeutics, Inc. (-8.80), greater than Addex Therapeutics Ltd (-81.79), less than Achilles Therapeutics plc (-0.45), greater than NextCure, Inc. (-0.65), less than CytomX Therapeutics, Inc. (9.19), greater than Neoleukin Therapeutics, Inc. (-0.98), less than Spero Therapeutics, Inc. (4.06), greater than Assembly Biosciences, Inc. (-2.10), greater than Replimune Group, Inc. (-3.26), greater than Nuvectis Pharma, Inc. (-4.95), less than Lyra Therapeutics, Inc. (-0.18), greater than Gossamer Bio, Inc. (-2.55), greater than Crinetics Pharmaceuticals, Inc. (-15.40), less than Inhibrx, Inc. (0.13), greater than Merus N.V. (-18.45), greater than Lyell Immunopharma, Inc. (-1.42), greater than Generation Bio Co. (-0.92), greater than Erasca, Inc. (-3.94), greater than C4 Therapeutics, Inc. (-3.44), greater than Edgewise Therapeutics, Inc. (-14.14),

Build a custom stock screener for Kronos Bio, Inc. (KRON) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kronos Bio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kronos Bio, Inc. (KRON) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kronos Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.